Decheng Capital
Venture capitalActively deployingMenlo Park · Seed–Growth · 16 people tracked
Also known as Decheng Capital China Life Sciences USD · Decheng Capital Global Life Sciences · DECHENG CAPITAL LLC
Investment thesis
Decheng Capital focuses on the healthcare and life science sectors, backing early-stage life science companies with breakthrough technologies as well as growth-stage healthcare companies that have an established market presence. The firm views the rapid growth of the healthcare industry and advances in life science research as a historic opportunity, and combines capital with strategic support to help build successful companies globally. It draws on a team with complementary expertise and backing from prominent limited partners to create value for both investors and entrepreneurs.
Source: firm website, verified Aug 7, 2026.
Team · 16 people
from the firm's website & public directories
What they invest in
from 25 of 95 portfolio companiesBiotech ×17Healthtech ×12Medical Devices ×8AI & Machine Learning ×6Deep Tech ×3Digital Health ×2Enterprise Software ×2SaaS ×2
HQs:United States×22Canada×1
Investments · 95 tracked
founders shown can be your intro pathAardvark Therapeutics is a biopharmaceutical company developing therapeutics, with programs and expertise spanning metabolic disease, obesity, diabetes, and oncology.
BiotechHealthtechSan Diego, US
Zachary Hornby(Director)Jerel Banks(Director)Tien-Li Lee(Executive Officer, Director)Jeffrey Chi(Director)Henry Ji(Director)Bob Shin(Director)
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Sarah Krevans(Director)Gregory Summe(Director)Josh Ofman(Executive Officer)Steve Mizell(Director)
Board seatMin Cui· per SEC Form D
Aadi Bioscience is a commercial-stage biopharmaceutical company developing therapies for cancer patients with mTOR pathway driver alterations, with an initial focus on advanced malignant PEComa, an ultra-rare cancer.
BiotechHealthtechMorristown, US
Baiteng Zhao(Director)Scott Giacobello(Executive Officer)Caley Castelein(Director)Richard Maroun(Director)Bryan Ball(Executive Officer)Behzad Aghazadeh(Director)
Adaptive Biotechnologies decodes the genetic patterns of the adaptive immune system to develop clinical products for diagnosing and treating disease.
BiotechDigital HealthHealthtechMedical DevicesSeattle, US
Arnold Levine(Director)Chad Robins(Executive Officer, Director)Andris Zoltners(Director)Tom Willis(Director)Kathleen Determann(Executive Officer)Peter Neupert(Director)
Health Catalyst provides data analytics, AI-powered insights, and healthcare solutions to help hospital systems and healthcare organizations improve clinical, financial, and operational outcomes.
AI & Machine LearningData & InfrastructureHealthtech
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.
Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US
Fabian Gerlinghaus(Co-Founder and Chief Executive Officer)inOmar Kurdi(Co-Founder and President)inVictor Tong(Director)in
BoardJustin Butler(Director)
Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection.
BiotechDeep TechHealthtech
David Johnson(Chief Executive Officer)Clayton Knox(President)Katti Jessen(SVP, Translational Sciences)Yakov Kogan(Head of Operations)Brian Lannutti(Research & Development Leadership)Langdon Miller(Clinical Development Leadership)
HealthtechHouston, US
Kengo Takishima(Executive Officer, Director)Brendan Lee(Director)Victor Tong(Director)Xiangmin Cui(Director)Goki Ishikawa(Director)Joel Kaufman(Executive Officer)
Board seatXiangmin Cui· per SEC Form D
West Hills, US
Board seatXiangmin Cui· per SEC Form D · $141.8M raise · filed Apr 2024
San Francisco, US
Lars Steinmetz(Director)Utkan Demirci(Director)Xiangmin Cui(Director)Martin Pieprzyk(Executive Officer)Victor Tong(Director)
Board seatVictor E. Tong· per SEC Form D · $25.1M raise · filed Apr 2024
BiotechFremont, US
Feng Wang-Johanning(Executive Officer, Director)Xiangmin Cui(Director)Gary Johanning(Executive Officer)Peter Colabuono(Director)
Board seatXiangmin Cui· per SEC Form D · $6M raise · filed Jan 2023
Company that went public on NASDAQ in 2019 (ADPT)
BiotechSeattle, US
Dr. Mitchell H Gold(Executive Officer, Director)Michael Kornacker(Executive Officer, Director)Ryan Swanson(Executive Officer, Director)David Miller(Executive Officer, Director)Jay Venkatesan(Director)James Paul Rickey(Senior Vice President and Chief Financial Officer)
Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)
BiotechEnglewood, US
Jarrett T. Disbrow(Executive Officer)Michael Macaluso(Director)Joshua R. Disbrow(Executive Officer)Gregory A. Gould(Executive Officer)
Company that went public on NASDAQ in 2024 (CGON)
Hummingbird Bioscience develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), using proprietary linker-payload and biologics discovery platforms.
BiotechHealthtech
Biopharmaceutical company that went public on NASDAQ in 2015 (HKSE: 1530)
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Shelly Guyer(Executive Officer)Eric Aguiar(Director)Sean George(Executive Officer, Director)Christine Gorjanc(Director)Geoffrey Crouse(Director)Lee Bendekgey(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Apr 2024
Disclosed stake · filed Feb 2021
5 insider ownership filings (Forms 3/4/5)
at Aardvark Therapeutics, Inc. (AARD), CG Oncology, Inc. (CGON)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Decheng Capital invest at?
- Decheng Capital invests at the Seed, Series A, Growth stages.
- What sectors does Decheng Capital focus on?
- Decheng Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Decheng Capital located?
- Decheng Capital is headquartered in Menlo Park, US.
- Does Decheng Capital lead rounds?
- Decheng Capital typically participates in rounds rather than leading them.
Similar investors
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.